Energy levels, radiative rates and electron impact excitation rates for transitions in He-like Cl XVI, K XVIII, Ca XIX and Sc XX.

We report calculations of energy levels, radiative rates and electron impact excitation cross
sections and rates for transitions in He-like Cl XVI, K XVIII, Ca XIX and Sc XX. The grasp
(general-purpose relativistic atomic structure package) is adopted for calculating energy levels
and radiative rates. To determine the collision strengths and subsequently the excitation rates,
the Dirac atomic R-matrix code (darc) is used. Oscillator strengths, radiative rates and line
strengths are reported for all E1, E2, M1 and M2 transitions among the lowest 49 levels of
each ion. Collision strengths are averaged over a Maxwellian velocity distribution and the
effective collision strengths obtained listed over a wide temperature range up to 107.4 K.
Comparisons are made with similar data obtained from the flexible atomic code (fac) to
highlight the importance of resonances, included in calculations with darc, in the
determination of effective collision strengths. Discrepancies between the collision strengths
from darc and fac, particularly for forbidden transitions, are also discussed. Additionally,
theoretical lifetimes are listed for all the 49 levels of the above four ions.

Feedback via Ca��⁺-activated ion channels modulates endothelin 1 signaling in retinal arteriolar smooth muscle

PURPOSE: To investigate the role of feedback by Ca��?-sensitive plasma-membrane ion channels in endothelin 1 (Et1) signaling in vitro and in vivo. Methods. Et1 responses were imaged from Fluo-4-loaded smooth muscle in isolated segments of rat retinal arteriole using two-dimensional (2-D) confocal laser microscopy. Vasoconstrictor responses to intravitreal injections of Et1 were recorded in the absence and presence of appropriate ion channel blockers using fluorescein angiograms imaged using a confocal scanning laser ophthalmoscope. Results. Et1 (10 nM) increased both basal [Ca��?](i) and the amplitude and frequency of Ca��?-waves in retinal arterioles. The Ca��?-activated Cl?-channel blockers DIDS and 9-anthracene carboxylic acid (9AC) blocked Et1-induced increases in wave frequency, and 9AC also inhibited the increase in amplitude. Iberiotoxin, an inhibitor of large conductance (BK) Ca��?-activated K?-channels, increased wave amplitude in the presence of Et1 but had no effect on frequency. None of these drugs affected basal [Ca��?](i). The voltage-operated Ca��?-channel inhibitor nimodipine inhibited wave frequency and amplitude and also lowered basal [Ca��?](i) in the presence of Et1. Intravitreal injection of Et1 caused retinal arteriolar vasoconstriction. This was inhibited by DIDS but not by iberiotoxin or penitrem A, another BK-channel inhibitor. Conclusions. Et1 evokes increases in the frequency of arteriolar Ca��?-waves in vitro, resulting in vasoconstriction in vivo. These responses, initiated by release of stored Ca��?, also require positive feedback via Ca��?-activated Cl?-channels and L-type Ca��?-channels.

Energy levels, wavefunction compositions and electric dipole transitions in neutral Ca

A configuration-interaction approach, based on the use of B-spline basis sets combined with a model potential including monoelectronic and dielectronic core polarization effects, is employed to calculate term energies and wavefunctions for neutral Ca. Results are reported for singlet and triplet bound states, and some quasi-bound states above the lowest ionization limit, with angular momentum up to L = 4. Comparison with experiment and with other theoretical results shows that this method yields the most accurate energy values for neutral Ca obtained to date. Wavefunction compositions, necessary for labelling the levels, and the effects of semi-empirical polarization potentials on the wavefunctions are discussed, as are some recent identifications of doubly-excited states. It is shown that taking into account dielectronic core polarization changes the energies of the lowest terms in Ca significantly, in general by a few hundred cm(-1), the effect decreasing rapidly for the higher bound states. For Rydberg states with n approximate to 7 the accuracy of the results is often better than a few cm(-1). For series members (or perturbers) with a pronounced 3d character the error can reach 150 cm(-1). The wavefunctions are used to calculate oscillator strengths and lifetimes for a number of terms and these are compared with existing measurements. The agreement is good but points to a need for improved measurements.

A plasma membrane Ca<sup>2+-ATPase (PMCA) from the liver fluke, Fasciola hepatica</em>

Fasciolosis is a parasitic infection by the liver fluke Fasciola hepatica, which costs the global agricultural community over US $2 billion per year. Its prevalence is rising due to factors such as climate change and drug resistance. ATP-dependent membrane transporters are considered good potential drug targets as they are essential for cellular processes and are in an exposed, accessible position in the cell. Immunolocalisation studies demonstrated that a plasma membrane calcium ATPase (PMCA) was localised to the parenchymal tissue in F. hepatica. The coding sequence for a F. hepatica PMCA (FhPMCA) has been obtained. This sequence encodes a 1,163 amino acid protein which contains motifs which are commonly conserved in PMCAs. Molecular modelling predicted that the protein has 10 transmembrane segments which include a potential calcium ion binding site and phosphorylation motif. FhPMCA interacts with the calmodulin-like protein FhCaM1, but not the related proteins FhCaM2 or FhCaM3, in a calcium-ion dependent manner. This interaction occurs through a region in the C-terminal region of FhPMCA which most likely adopts an a-helical conformation. When FhPMCA was heterologously expressed in a budding yeast strain deleted for its PMCA (Pmc1p), it restored viability. Microsomes prepared from these yeast cells had calcium ion stimulated ATPase activity which was inhibited by the known PMCA inhibitors, bisphenol and eosin. The potential of FhPMCA as a new drug target is discussed.